Wells Fargo Upgrades Relay Therapeutics (RLAY) to Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts RLAY Hot Sheet
Price: $18.12 -0.33%
Rating Summary:
16 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 24 | New: 56
Rating Summary:
16 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 24 | New: 56
Join SI Premium – FREE
Wells Fargo analyst Eva Fortea Verdejo upgraded Relay Therapeutics (NASDAQ: RLAY) from Equal Weight to Overweight with a price target of $13.00.
For an analyst ratings summary and ratings history on Relay Therapeutics click here. For more ratings news on Relay Therapeutics click here.
Shares of Relay Therapeutics closed at $7.79 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JetBlue Airways (JBLU) Misses Q3 EPS by 6c, Misses on Revenue
- Noble Corp (NE) Misses Q3 EPS by 81c; Offers Outlook
- Elemental Royalty closes four-asset acquisition, expands credit line to $250M
Create E-mail Alert Related Categories
UpgradesRelated Entities
Wells Fargo, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
